Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosnilimab in Alopecia Areata
NCT05205070Phase 2Unknown
- Sponsor
- AnaptysBio, Inc.
- Start
- Dec 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alopecia areata comparing Rosnilimab with Placebo (2 arms). Primary endpoint: Change from baseline in Severity of Alopecia Tool score at 24 weeks. Status: unknown.
02
Drugs
rosnilimab
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05205070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205070.